Konruns 康辰药业
30 significant filings since 29 May 2026: 1 on litigation, 19 on equity incentive and 9 on buyback, and 1 other kind. The latest, on 25 Sep 2026: 康辰药业关于涉及仲裁结果的公告.
自 29 May 2026 起有 30 份重大公告：litigation 1 份、equity incentive 19 份、buyback 9 份，另有 1 类。最新一份（25 Sep 2026）：康辰药业关于涉及仲裁结果的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 8 May 2023 | 华金证券 | 周平 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 太平洋 | 谭紫媚,张懿 | Buy 买入 | 8 Sep 2026 | 3 | — |
| 中航证券 | 李蔚 | Buy 买入 | 6 Sep 2026 | 4 | — |
| 山西证券 | 邓周宇,魏赟,张智勇 | Buy 买入 | 28 May 2026 | 1 | — |
| 中银证券 | 刘恩阳,苏雪儿 | Buy 买入 | 29 Apr 2026 | 1 | — |
| 西南证券 | 杜向阳,汤泰萌 | Unrated | 24 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 10 reports. 每行为该券商近十二个月的最新研报；10 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。